{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:01:04Z","timestamp":1742396464887},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T00:00:00Z","timestamp":1406073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["cancer imaging"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1470-7330-14-26","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T21:51:19Z","timestamp":1576014679000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know"],"prefix":"10.1186","volume":"14","author":[{"given":"Frederico F","family":"Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrillo","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyothi","family":"Jagannathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciaran","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"O\u2019Regan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Shinagare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Ramaiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,23]]},"reference":[{"key":"128_CR1","first-page":"1","volume-title":"Biologic and pharmacologic basis of cancer chemotherapy and biotherapy","author":"R Skeel","year":"2007","unstructured":"Skeel R, Khlief S Handbook of Cancer Chemotherapy. 7th edition. chapter 1. In Biologic and pharmacologic basis of cancer chemotherapy and biotherapy. Philadelphia: Lippincott Williams and Wilkins, a Wolters Kluwer business; 2007:1\u201331."},{"key":"128_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1378\/chest.127.4.1136","volume":"127","author":"JP Wisnivesky","year":"2005","unstructured":"Wisnivesky JP, Yankelevitz D, Henschke CI: Stage of lung cancer in relation to its size: part 2. Evidence. Chest 2005, 127: 1136\u20131139.","journal-title":"Evidence. Chest"},{"key":"128_CR3","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25: 1753\u20131759.","journal-title":"J Clin Oncol"},{"key":"128_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson D: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346: 92\u201398.","journal-title":"N Engl J Med"},{"key":"128_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2008.05.015","volume":"63","author":"M Reck","year":"2009","unstructured":"Reck M, Crino L: Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 2009, 63: 1\u20139.","journal-title":"Lung Cancer"},{"key":"128_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0169-5002(04)80039-4","volume":"46","author":"T Le Chevalier","year":"2004","unstructured":"Le Chevalier T, Lynch T: Adjuvant treatment of lung cancer: current status and potential applications of new regimens. Lung Cancer 2004, 46: 33\u201339.","journal-title":"Lung Cancer"},{"issue":"3","key":"128_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3816\/CLC.2004.n.029","volume":"6","author":"MA Socinski","year":"2004","unstructured":"Socinski MA: Adjuvant therapy of resected non-small cell lung cancer. Clin Lung Cancer 2004, 6(3):162\u2013169.","journal-title":"Clin Lung Cancer"},{"key":"128_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.13-S2-4","volume":"13","author":"H Choi","year":"2008","unstructured":"Choi H: Response evaluation of gastrointestinal stromal tumors. Oncologist 2008, 13: 4\u20137.","journal-title":"Oncologist"},{"key":"128_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/cncr.10741","volume":"95","author":"ER Fisher","year":"2002","unstructured":"Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N: Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002, 95: 681\u2013695.","journal-title":"Cancer"},{"key":"128_CR10","first-page":"297","volume":"180","author":"DM Sataloff","year":"1995","unstructured":"Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995, 180: 297\u2013306.","journal-title":"J Am Coll Surg"},{"key":"128_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2967\/jnumed.108.056655","volume":"50","author":"B Zhao","year":"2009","unstructured":"Zhao B, Schwartz L, Larson S: Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med 2009, 50: 239\u2013249.","journal-title":"J Nucl Med"},{"key":"128_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2967\/jnumed.108.052712","volume":"49","author":"B Goudarzi","year":"2008","unstructured":"Goudarzi B, Wahl R: PET\/CT evaluation of bronchioloalveolar carcinoma: correlation with CT and FDG\/PET findings. J Nucl Med. 2008, 49: 363.","journal-title":"J Nucl Med"},{"key":"128_CR13","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2214\/ajr.183.6.01831619","volume":"183","author":"H Choi","year":"2004","unstructured":"Choi H, Charnsangavej C, Faria S: CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004, 183: 1619\u20131628.","journal-title":"AJR Am J Roentgenol"},{"key":"128_CR14","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S1076-6332(00)80629-7","volume":"7","author":"WW Li","year":"2000","unstructured":"Li WW: Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol 2000, 7: 800\u2013811.","journal-title":"Acad Radiol"},{"key":"128_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1148\/radiology.188.2.8327686","volume":"188","author":"KA Miles","year":"1993","unstructured":"Miles KA, Hayball MP, Dixon AK: Functional images of hepatic perfusion obtained with dynamic CT. Radiology 1993, 188: 405\u2013411.","journal-title":"Radiology"},{"key":"128_CR16","first-page":"63","volume":"20","author":"A Cenic","year":"1999","unstructured":"Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY: Dynamic CT measurement of cerebral blood flow: a validation study. Am J Neuroradiol 1999, 20: 63\u201373.","journal-title":"Am J Neuroradiol"},{"key":"128_CR17","first-page":"462","volume":"21","author":"A Cenic","year":"2000","unstructured":"Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY: A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. Am J Neuroradiol 2000, 21: 462\u2013470.","journal-title":"Am J Neuroradiol"},{"key":"128_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/00004424-199410000-00002","volume":"29","author":"H Hattori","year":"1994","unstructured":"Hattori H, Miyoshi T, Okada J, Yoshikawa K, Arimizu N, Hattori N: Tumor blood flow measured using dynamic computed tomography. Invest Radiol 1994, 29: 873\u2013876.","journal-title":"Invest Radiol"},{"key":"128_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/00004424-198805000-00003","volume":"23","author":"RG Gould","year":"1988","unstructured":"Gould RG, Lipton MJ, McNamara MT, Sievers RE, Koshold S, Higgins CB: Measurement of regional myocardial blood flow in dogs by ultrafast CT. Invest Radiol 1988, 23: 348\u2013353.","journal-title":"Invest Radiol"},{"issue":"Suppl. 5","key":"128_CR20","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1097\/00004424-199311001-00023","volume":"28","author":"MJ Blomley","year":"1993","unstructured":"Blomley MJ, Coulden R, Bufkin C, Lipton MJ, Dawson P: Contrast bolus dynamic computed tomography for the measurement of solid organ perfusion. Invest Radiol 1993, 28(Suppl. 5):S72-S77.","journal-title":"Invest Radiol"},{"key":"128_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/00004728-199505000-00016","volume":"19","author":"MJ Blomley","year":"1995","unstructured":"Blomley MJ, Coulden R, Dawson P, Kormano M, Donlan P, Bufkin C: Liver perfusion studied with ultrafast CT. J Comput Assist Tomogr 1995, 19: 424\u2013433.","journal-title":"J Comput Assist Tomogr"},{"key":"128_CR22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01616412.2000.11740700","volume":"22","author":"J Gillard","year":"2000","unstructured":"Gillard J, Antoun N, Burnet N, Pickard J: Assessment of quantitative computed tomographic cerebral perfusion imaging with positron emission tomography. Neurol Res 2000, 22: 457\u2013464.","journal-title":"Neurol Res"},{"key":"128_CR23","first-page":"905","volume":"22","author":"M Wintermark","year":"2001","unstructured":"Wintermark M, Thiran JP, Maeder P, Schnyder P, Meuli R: Simultaneous measurement of regional cerebral blood flow by perfusion CT and stable xenon CT: a validation study. Am J Neuroradiol 2001, 22: 905\u2013914.","journal-title":"Am J Neuroradiol"},{"key":"128_CR24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/00004728-199907000-00003","volume":"23","author":"DG Nabavi","year":"1999","unstructured":"Nabavi DG, Cenic A, Dool J, Smith RM, Espinosa F, Craen RA, Gelb AW, Lee TY: Quantitative assessment of cerebral hemodynamics using CT: stability, accuracy, and precision studies in dogs. J Comput Assist Tomogr 1999, 23: 506\u2013515.","journal-title":"J Comput Assist Tomogr"},{"key":"128_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1259\/bjr.74.882.740552","volume":"74","author":"JH Gillard","year":"2001","unstructured":"Gillard JH, Antoun NM, Burnet NG, Pickard JD: Reproducibility of quantitative CT perfusion imaging. Br J Radiol 2001, 74: 552\u2013555.","journal-title":"Br J Radiol"},{"issue":"3","key":"128_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1200\/JCO.2008.16.2545","volume":"27","author":"SJ Crabb","year":"2009","unstructured":"Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Goodman SL, Pepper MS: Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non\u2013small-cell lung cancer. J Clin Oncol 2009, 27(3):404\u2013410.","journal-title":"J Clin Oncol"},{"key":"128_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JTO.0b013e318168c7e9","volume":"3","author":"EM Marom","year":"2008","unstructured":"Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR Jr, Onn A: Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 2008, 3: 351\u2013357.","journal-title":"J Thorac Oncol"},{"key":"128_CR28","doi-asserted-by":"publisher","first-page":"31S","DOI":"10.2967\/jnumed.108.057216","volume":"50","author":"R Hicks","year":"2009","unstructured":"Hicks R: Role of 18 F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 2009, 50: 31S-42S.","journal-title":"J Nucl Med"},{"key":"128_CR29","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ijc.22012","volume":"119","author":"S Fujita","year":"2006","unstructured":"Fujita S, Mio T, Sonobe M: Accuracy of epidermal growth factor receptor mutation analysis on the basis of small biopsy specimens in patients with nonsmall cell lung cancer. Int J Cancer 2006, 119: 1751\u20131752.","journal-title":"Int J Cancer"},{"key":"128_CR30","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/j.1349-7006.2006.00216.x","volume":"97","author":"H Kimura","year":"2006","unstructured":"Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K: High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006, 97: 642\u2013648.","journal-title":"Cancer Sci"},{"key":"128_CR31","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1158\/1078-0432.CCR-05-2324","volume":"12","author":"H Kimura","year":"2006","unstructured":"Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small cell lung cancer. Clin Cancer Res 2006, 12: 3915\u20133921.","journal-title":"Clin Cancer Res"},{"key":"128_CR32","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ijc.21458","volume":"118","author":"JY Shih","year":"2006","unstructured":"Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, Hsu YC, Chen KY, Su WP, Yang PC: Epidermal growth factor receptor mutations in needle biopsy\/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006, 118: 963\u2013969.","journal-title":"Int J Cancer"},{"key":"128_CR33","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s00330-004-2250-3","volume":"14","author":"M Montaudon","year":"2004","unstructured":"Montaudon M, Latrabe V, Pariente A, Corneloup O, Begueret H, Laurent F: Factors influencing accuracy of CT-guided percutaneous biopsies of pulmonary lesions. Eur Radiol 2004, 14: 1234\u20131240.","journal-title":"Eur Radiol"},{"key":"128_CR34","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1378\/chest.07-0851","volume":"133","author":"B Vahid","year":"2008","unstructured":"Vahid B, Marik P: Pulmonary complication of novel antineoplastic agents for solid tumors. Chest 2008, 133: 528\u2013538.","journal-title":"Chest"},{"key":"128_CR35","first-page":"81","volume-title":"Katzenstein and Askin\u2019s surgical pathology of non-neoplastic lung disease, Volume 4","author":"JL Meyers","year":"1997","unstructured":"Meyers JL: Pathology of drug-induced lung disease. In Katzenstein and Askin\u2019s surgical pathology of non-neoplastic lung disease, Volume 4. 3rd edition. Edited by: Katzenstein AA, Askin FB. Philadelphia, Pa: Saunders; 1997:81\u2013111.","edition":"3"},{"key":"128_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005382-199101000-00003","volume":"6","author":"GG Pietra","year":"1991","unstructured":"Pietra GG: Pathologic mechanisms of drug-induced lung disorders. J Thorac Imaging 1991, 6: 1\u20137.","journal-title":"J Thorac Imaging"},{"key":"128_CR37","first-page":"551","volume-title":"Spencer\u2019s Pathology of the Lung","author":"JM Kay","year":"1996","unstructured":"Kay JM: Drug-induced lung disease. In Spencer\u2019s Pathology of the Lung. 5th edition. Edited by: Hasleton PS. New York, NY: McGraw-Hill; 1996:551\u2013595.","edition":"5"},{"key":"128_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","volume":"361","author":"A Inoue","year":"2003","unstructured":"Inoue A, Saijo Y, Maemondo M: Severe acute interstitial pneumonia and gefitinib. Lancet 2003, 361: 137\u2013139.","journal-title":"Lancet"},{"key":"128_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0169-5002(03)00043-6","volume":"40","author":"A Inoue","year":"2003","unstructured":"Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y: Diffuse alveolar damage after ZD 1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 2003, 40: 339\u2013342.","journal-title":"Lung Cancer"},{"key":"128_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s10147-004-0418-0","volume":"9","author":"F Ohyanagi","year":"2004","unstructured":"Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y: Acute gefitinib-induced pneumonitis. Int J Clin Oncol 2004, 9: 406\u2013409.","journal-title":"Int J Clin Oncol"},{"key":"128_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.lungcan.2003.09.016","volume":"43","author":"K Sumpter","year":"2004","unstructured":"Sumpter K, Harper-Wynne C, O'Brien M, Congleton J: Severe acute interstitial pneumonia and gefitinib. Lung Cancer 2004, 43: 367\u2013368.","journal-title":"Lung Cancer"},{"key":"128_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1183\/09031936.03.00098503","volume":"22","author":"R Ieki","year":"2003","unstructured":"Ieki R, Saitoh E, Shibuya M: Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003, 22: 179\u2013181.","journal-title":"Eur Respir J"},{"key":"128_CR43","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2005.04.055","volume":"23","author":"NC Nagaria","year":"2005","unstructured":"Nagaria NC, Cogswell J, Choe JK, Kasimis B: Side effects and good effects from new chemotherapeutic agents: Gefitinib-induced interstitial fibrosis. J Clin Oncol 2005, 23: 2423\u20132424.","journal-title":"J Clin Oncol"},{"key":"128_CR44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1155\/2007\/832605","volume":"14","author":"B Vahid","year":"2007","unstructured":"Vahid B, Esmaili A: Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J 2007, 14: 167\u2013170.","journal-title":"Can Respir J"},{"key":"128_CR45","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1440-1843.2006.00907.x","volume":"11","author":"B Vahid","year":"2006","unstructured":"Vahid B, Mehrotra A: Trastuzumab (Herceptin)-associated lung injury. Respirology 2006, 11: 655\u2013658.","journal-title":"Respirology"},{"key":"128_CR46","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1183\/09031936.03.00035502","volume":"21","author":"E Radzikowska","year":"2003","unstructured":"Radzikowska E, Szczepulska E, Chabowski M, Bestry I: Organising pneumonia caused by trastuzumab (Herceptin) therapy for breast cancer. Eur Respir J 2003, 21: 552\u2013555.","journal-title":"Eur Respir J"},{"key":"128_CR47","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1200\/JCO.2004.06.557","volume":"22","author":"D Tripathy","year":"2004","unstructured":"Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004, 22: 1063\u20131070.","journal-title":"J Clin Oncol"},{"key":"128_CR48","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/cncr.20950","volume":"103","author":"G Clamon","year":"2005","unstructured":"Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, Green M: Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2:39810: a phase II trial of Cancer and Leukemia Group B. Cancer 2005, 103: 1670\u20131675.","journal-title":"Cancer"},{"key":"128_CR49","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353: 1673\u20131684.","journal-title":"N Engl J Med"},{"key":"128_CR50","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","volume":"42","author":"I Duran","year":"2006","unstructured":"Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA: Characterization of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006, 42: 1875\u20131880.","journal-title":"Eur J Cancer"},{"key":"128_CR51","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22: 909\u2013918.","journal-title":"J Clin Oncol"},{"key":"128_CR52","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.healun.2007.01.017","volume":"26","author":"M Rothenburger","year":"2007","unstructured":"Rothenburger M, Teerling E, Bruch C, Lehmkuhl H, Suwelack B, Bara C, Wichter T, Hinder F, Schmid C, Stypmann J: SO: Calcinurin inhibitor-free immunosuppression using everolimus (certican) in maintenance heart transplant recipients: 6 months follow-up. J Heart Lung Transplant 2007, 26: 250\u2013257.","journal-title":"J Heart Lung Transplant"},{"key":"128_CR53","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0761-8425(04)71304-2","volume":"21","author":"V Jullien","year":"2004","unstructured":"Jullien V, Perrin C, Peyrade F, Lemoigne F, Chichmanian RM, Blaive B: Alveolar hypoxemic interstitial pneumonia related to rituximab therapy. Rev Mal Respir 2004, 21: 407\u2013410.","journal-title":"Rev Mal Respir"},{"key":"128_CR54","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1056\/NEJM200306263482619","volume":"348","author":"C Burton","year":"2003","unstructured":"Burton C, Kaczmarski R, Jan-Mohamed R: Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003, 348: 2690\u20132691.","journal-title":"N Engl J Med"},{"key":"128_CR55","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3109\/10428190109097760","volume":"42","author":"S Kanelli","year":"2001","unstructured":"Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE: Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 2001, 42: 1329\u20131337.","journal-title":"Leuk Lymphoma"},{"key":"128_CR56","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/ajh.20135","volume":"77","author":"R Swords","year":"2004","unstructured":"Swords R, Power D, Fay M, O'Donnell R, Murphy PT: Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004, 77: 103\u2013104.","journal-title":"Am J Hematol"},{"key":"128_CR57","first-page":"321","volume":"133","author":"JA Cooper Jr","year":"1986","unstructured":"Cooper JA Jr, White DA, Matthay RA: Drug-induced pulmonary disease. 1. Cytotoxic drugs. Am Rev Resp Dis 1986, 133: 321\u2013340.","journal-title":"Am Rev Resp Dis"},{"issue":"1","key":"128_CR58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0033-8389(03)00109-X","volume":"40","author":"JJ Erasmus","year":"2002","unstructured":"Erasmus JJ, McAdams HP, Rossi SE: High-resolution CT of drug-induced lung disease. Radiol Clin North Am 2002, 40(1):61\u201372.","journal-title":"Radiol Clin North Am"},{"key":"128_CR59","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1148\/radiographics.16.5.8888388","volume":"16","author":"HP McAdams","year":"1996","unstructured":"McAdams HP, Rosado-de-Christenson ML, Wehunt WD, Fishback NF: The alphabet soup revisited: the chronic interstitial pneumonias in the 1990s. Radiographics 1996, 16: 1009\u20131033.","journal-title":"Radiographics"},{"key":"128_CR60","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/JCO.1998.16.1.93","volume":"16","author":"G Bonadonna","year":"1998","unstructured":"Bonadonna G, Valagussa P, Brambilla C: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998, 16: 93\u2013100.","journal-title":"J Clin Oncol"},{"key":"128_CR61","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004, 22: 2184\u20132191.","journal-title":"J Clin Oncol"},{"key":"128_CR62","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355: 2542\u20132550.","journal-title":"N Engl J Med"},{"key":"128_CR63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1634\/theoncologist.9-suppl_1-19","volume":"9","author":"RS Herbst","year":"2004","unstructured":"Herbst RS, Sandler AB: Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 2004, 9: 19\u201326.","journal-title":"Oncologist"},{"key":"128_CR64","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD: Eisenberg: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347: 472\u2013480.","journal-title":"N Engl J Med"},{"issue":"24","key":"128_CR65","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354(24):2531\u20132541.","journal-title":"N Engl J Med"},{"issue":"12","key":"128_CR66","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Pasquini R, Hamerschlak N: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007, 109(12):5143\u20135150.","journal-title":"Blood"},{"key":"128_CR67","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini L: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N Engl J Med 2002, 346: 645\u2013652.","journal-title":"N Engl J Med"},{"key":"128_CR68","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/00043426-200211000-00020","volume":"24","author":"R Goldsby","year":"2002","unstructured":"Goldsby R, Pulsipher M, Adams R, Coffin C, Albritton K, Wagner L: Unexpected pleural effusions in 3 pediatric patients treated with STI-571. J Pediatr Hematol Oncol 2002, 24: 694\u2013695.","journal-title":"J Pediatr Hematol Oncol"},{"key":"128_CR69","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21: 60\u201365.","journal-title":"J Clin Oncol"},{"key":"128_CR70","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/annonc\/mdi208","volume":"16","author":"R Midgley","year":"2005","unstructured":"Midgley R, Kerr D: Bevacizumab\u2014current status and future directions. Ann Oncol 2005, 16: 999\u20131004.","journal-title":"Ann Oncol"},{"key":"128_CR71","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1634\/theoncologist.12-12-1443","volume":"12","author":"C Widakowich","year":"2007","unstructured":"Widakowich C, de Castro G Jr, de Azambuja E, Dinh P: Side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007, 12: 1443\u20131455.","journal-title":"Oncologist"},{"key":"128_CR72","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20: 1215\u20131221.","journal-title":"J Clin Oncol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1470-7330-14-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1470-7330-14-26\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1470-7330-14-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T21:51:22Z","timestamp":1576014682000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/1470-7330-14-26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,23]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["128"],"URL":"https:\/\/doi.org\/10.1186\/1470-7330-14-26","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,23]]},"assertion":[{"value":"13 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"26"}}